I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Al Katib, Ayad ^a   Arnold, Alan A ^b   Aboukameel, Amro ^a   Sosin, Angela ^a   Smith, Peter ^c   Mohamed, Anwar N ^a   Beck, Frances W ^a   Mohammad, Ramzi M ^d  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

^d KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 7 METHOXY 8 (2 METHYLNICOTINAMIDO) BETA CARBOLINE; CASPASE 3; CASPASE 8; CYCLOPHOSPHAMIDE; DOXORUBICIN; I KAPPA KINASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PREDNISONE; PROTEIN IKK 2; TRANSCRIPTION FACTOR RELA; TUMOR PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE; ANTITUSSIVE AGENT; DRUG DERIVATIVE; ENZYME INHIBITOR; I KAPPA B KINASE; NICOTINAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL KILLING; CELL NUCLEUS; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; DOSAGE SCHEDULE COMPARISON; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; FOLLICULAR LYMPHOMA; GENE TRANSLOCATION; IC 50; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; LYMPHOMA CELL; MAXIMUM TOLERATED DOSE; MICROTUBULE; MICROTUBULE DISRUPTION; MONOTHERAPY; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCID MOUSE; SINGLE DRUG DOSE; TUMOR XENOGRAFT; ANIMAL; CELL CYCLE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; MOUSE MUTANT; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTITUSSIVE AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENZYME INHIBITORS; FEMALE; FLOW CYTOMETRY; HUMANS; I-KAPPA B KINASE; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; MICE; MICE, SCID; MICROSCOPY, FLUORESCENCE; NIACINAMIDE; VINCRISTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956483333     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-228     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2008, 59:225-249.
2. A clinical evaluation of the International Lymphoma Study Group classification of non Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997, 89:3909-3918.
3. Young GA, Iland HJ. Clinical perspectives in lymphoma. Intern Med J 2007, 37:478-484. 10.1111/j.1445-5994.2007.01402.x, 17547725.
4. Tsartsidze E, Betaneli M, Sharikadze N, Shavidze N, Seskuria N. Treatment of aggressive non-Hodgkin's lymphomas. Georgian Med News 2007, 145:30-33.
5. Schulz H, Bohlius J, Skoetz N, Trelle S, Kober T, Reiser M, Dreyling M, Herold M, Schwarzer G, Hallek M, Engert A. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Cochrane Database Syst Rev 2007, 4:CD003805.
6. Buske C, Weigert O, Dreyling M, Unterhalt M, Hiddemann W. Current status and perspective of antibody therapy in follicular lymphoma. Haematologica 2006, 91:104-112.
7. Bernal-Mizrachi L, Lovly CM, Ratner L. The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphoma. Proc Natl Acad Sci USA 2006, 103:9220-9225. 10.1073/pnas.0507809103, 1482593, 16751281.
8. Hayden MS, Ghosh S. Shared principles in NF-kB signaling. Cell 2008, 132:344-362. 10.1016/j.cell.2008.01.020, 18267068.
9. Basseres DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006, 25:6817-6830. 10.1038/sj.onc.1209942, 17072330.
10. Mayo MW, Baldwin AS. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 2000, 1470:M55-62.
11. Escarcega RO, Fuentes-Alexandro S, García-Carrasco M, Gatica A, Zamora A. The transcription factor nuclear factor-kappa B and cancer. Clin Oncol (R Coll Radiol) 2007, 19:154-161.
12. Heckman CA, Mehew JW, Boxer LM. NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 2002, 21:3898-3908. 10.1038/sj.onc.1205483, 12032828.
13. Heckman CA, Cao T, Somsouk L, Duan H, Mehew JW, Zhang CY, Boxer LM. Critical elements of the immunoglobulin heavy chain gene enhancers for deregulated expression of bcl-2. Cancer Res 2003, 63:6666-6673.
14. Duan H, Heckman CA, Boxer LM. The immunoglobulin heavy-chain gene 3' enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells. Oncogene 2007, 26:2635-2641. 10.1038/sj.onc.1210061, 17043638.
15. Baldwin AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996, 14:649-683. 10.1146/annurev.immunol.14.1.649, 8717528.
16. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436. 10.1038/nature04870, 16724054.
17. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001, 107:241-246. 10.1172/JCI11991, 199203, 11160144.
18. Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007, 109:2700-2707.
19. Braddock M. 11th annual Inflammatory and Immune Diseases Drug Discovery and Development Summit 12-13 March 2007, San Francisco, USA. Expert Opi Investig Drugs 2007, 16:909-917.
20. Hideshima T, Neri P, Tassone P, Yasui H, Ishitsuka K, Raje N, Chauhan D, Podar K, Mitsiades C, Dang L, Munshi N, Richardson P, Schenkein D, Anderson KC. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res 2006, 12:5887-5894. 10.1158/1078-0432.CCR-05-2501, 17020997.
21. Mohammad RM, Kucuk O, Aboukameel A, Ibrahim D, Doerge DR, Sarkar F, Al-Katib AM. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. Mol Cancer Ther 2003, 2:1361-1368.
22. Mujagic H, Chen SS, Geist R, Occhipinti SJ, Conger BM, Smith CA, Schuette WH, Shackney SE. Effects of vincristine on cell survival, cell cycle progression, and mitotic accumulation in asynchronously growing Sarcoma 180 cells. Cancer Res 1983, 43:3591-3597.
23. Shinwari Z, Manogaran PS, Alrokayan A, Al-Hussein KA, Aboussekhra A. Vincristine and lomustine induce apoptosis and p21(WAF1) up-regulation in medulloblastoma and normal human epithelial and fibroblast cells. J Neuro Oncol 2008, 87:123-132.
24. Wang L, MacDonald RC. Effects of microtubule-depolymerizing agents on the transfection of cultured vascular smooth muscle cells: enhanced expression with free drug and especially with drug-gene lipoplexes. Mol Ther 2004, 9:729-737. 10.1016/j.ymthe.2004.02.009, 15120334.
25. Mohammad R, Abubakr Y, Dan M, Aboukameel A, Chow C, Mohamed A, Hamdy N, Al-Katib A. Bcl-2 Antisense oligonucleotides are effective against systemic but not central nervous system disease in Severe Combined Immuno Deficient mice bearing human t(14;18) follicular lymphoma. Clin Cancer Res 2002, 8:1277-1283.
26. Garcia MG, Alaniz L, Lopes EC, Blanco G, Hajos SE, Alvarez E. Inhibition of NF-kappaB activity by BAY 11-7082 increases apoptosis in multidrug resistant leukemic T-cell lines. Leuk Res 2005, 29:1425-1434. 10.1016/j.leukres.2005.05.004, 15982733.
27. Greten FR, Karin M. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett 2004, 206:193-199. 10.1016/j.canlet.2003.08.029, 15013524.
28. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004, 3:17-26. 10.1038/nrd1279, 14708018.
29. Wen D, Nong Y, Morgan JG, Gangurde P, Bielecki A, Dasilva J, Keaveney M, Cheng H, Fraser C, Schopf L, Hepperle M, Harriman G, Jaffee BD, Ocain TD, Xu Y. A selective small molecule IκB kinase B inhibitor blocks nuclear factor κB- mediated inflammatory responses in human fibroblast- like synviocytes, Chondrocytes, and Mast Cells. J Pharmacol Exp Ther 2006, 317:989-1001. 10.1124/jpet.105.097584, 16525037.
30. Nakajima H, Fujiwara H, Furuichi Y, Tanaka K, Shimbara N. A novel small-molecule inhibitor of NF-kappaB signaling. Biochem Biophys Res Commun 2008, 368:1007-1013. 10.1016/j.bbrc.2008.01.166, 18275844.
31. Huang Y, Fang Y, Wu J, Dziadyk JM, Zhu X, Sui M, Fan W. Regulation of Vinca alkaloid-induced apoptosis by NF-κB/IκB pathway in human tumor cells. Mol Can Ther 2004, 3:271-277.
32. Chen X, Kandasamy K, Srivastava RK. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res 2003, 63:1059-1066.
33. Wuerzberger-Davis SM, Chang PY, Berchtold C, Miyamoto S. Enhanced G2-M arrest by nuclear factor-{kappa}B-dependent p21waf1/cip1 induction. Mol Cancer Res 2005, 3:345-353. 10.1158/1541-7786.MCR-05-0028, 15972853.
34. Bharti AC, Takada Y, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003, 101:1053-1062. 10.1182/blood-2002-05-1320, 12393461.
35. Sanda T, Iida S, Ogura H, Asamitsu K, Murata T, Bacon KB, Ueda R, Okamoto T. Growth inhibition of multiple myeloma cells by a novel IkappaB kinase inhibitor. Clin Cancer Res 2005, 11:1974-1982. 10.1158/1078-0432.CCR-04-1936, 15756023.
36. Mohammad RM, Mohamed AN, Smith MR, Jawadi NS, Al-Katib A. A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11). Cancer Gene Cytogene 1993, 70:62-67.
37. Al-Katib AM, Smith MR, Kamanda WS, Pettit GR, Hamdan M, Mohamed AN, Chelladurai B, Mohammad RM. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res 1998, 4:1305-1314.
38. Darzynkiewicz Z, Galkowski D, Zhao H. Analysis of apoptosis by cytometry using TUNEL assay. Methods 2008, 44:250-254. 10.1016/j.ymeth.2007.11.008, 2295206, 18314056.
39. Mohammad RM, Wayng S, Aboukameel A, Chen B, Wu X, Chen J, Al-Katib A. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL[(--)-gossypol] against diffuse large cell lymphoma. Mol Cancer Ther 2005, 4:13-21.
40. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55. 10.1016/0065-2571(84)90007-4, 6382953.